{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:41:39Z","timestamp":1791452499631,"version":"4.3.3"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lenacapavir, a first-in-class HIV capsid inhibitor, is under development by Gilead Sciences for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). This article responds to inquiries into Gilead's access efforts for low- and lower-middle-income countries and reviews the science behind lenacapavir and its investigational use for HIV prevention, the current state of Gilead's planning for equitable access, and the necessity for partnership to end the HIV epidemic. Clinical trial results are a culmination of years of dedicated science, and they are just the beginning; we look forward to sharing updates as milestones are reached. Gilead is committed to working with scientists, clinicians, communities, advocates, governments, and other stakeholders to achieve broad, sustainable global access to lenacapavir for HIV prevention, if approved. Lenacapavir holds potential for helping to end new HIV infections around the world, a potential that reflects the vision we have at Gilead: to end the HIV epidemic for everyone, everywhere.<\/jats:p>","DOI":"10.1093\/cid\/ciaf116","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:37:46Z","timestamp":1744202266000},"page":"555-560","source":"Crossref","is-referenced-by-count":14,"title":["Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-8438","authenticated-orcid":false,"given":"Jared M","family":"Baeten","sequence":"first","affiliation":[{"name":"Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025100602581370900_ciaf116-B1","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B2","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100602581370900_ciaf116-B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","author":"Kelley","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100602581370900_ciaf116-B5","author":"Feiger"},{"key":"2025100602581370900_ciaf116-B6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2025100602581370900_ciaf116-B7","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.2830","article-title":"Facilitating next-generation pre-exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the forum HIV prevention trial design project","volume":"114","author":"Parkin","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2025100602581370900_ciaf116-B9","doi-asserted-by":"crossref","first-page":"e0267780","DOI":"10.1371\/journal.pone.0267780","article-title":"Proactive strategies to optimize engagement of Black, Hispanic\/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)","volume":"17","author":"Cespedes","year":"2022","journal-title":"PLoS One"},{"key":"2025100602581370900_ciaf116-B10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1126\/science.adv1489","article-title":"The great work continues","volume":"386","author":"Thorp","year":"2024","journal-title":"Science"},{"key":"2025100602581370900_ciaf116-B11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"2025100602581370900_ciaf116-B12","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2025100602581370900_ciaf116-B13","author":"AVAC"},{"key":"2025100602581370900_ciaf116-B14"},{"key":"2025100602581370900_ciaf116-B15","author":"UNAIDS"},{"key":"2025100602581370900_ciaf116-B16","doi-asserted-by":"crossref","first-page":"13596535211068617","DOI":"10.1177\/13596535211068617","article-title":"Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe\u2014a business case","volume":"27","author":"Alton","year":"2022","journal-title":"Antivir Ther"},{"key":"2025100602581370900_ciaf116-B17","author":"Medicines Patent Pool"},{"key":"2025100602581370900_ciaf116-B18","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B19","author":"Funders Concerned About AIDS"},{"key":"2025100602581370900_ciaf116-B20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1377\/hlthaff.2024.00089","article-title":"Low- and middle-income countries experienced delays accessing new essential medicines, 1982\u20132024","volume":"43","author":"Wouters","year":"2024","journal-title":"Health Aff (Millwood)"},{"key":"2025100602581370900_ciaf116-B21","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B22","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B23","author":"World Health Organization"},{"key":"2025100602581370900_ciaf116-B24","author":"Gilead Sciences"},{"key":"2025100602581370900_ciaf116-B25","author":"AVAC"},{"key":"2025100602581370900_ciaf116-B26","author":"AVAC"},{"key":"2025100602581370900_ciaf116-B27","author":"AVAC"},{"key":"2025100602581370900_ciaf116-B28","author":"UNAIDS"},{"key":"2025100602581370900_ciaf116-B29","author":"Center for Strategic and International Studies"},{"key":"2025100602581370900_ciaf116-B30","author":"The Global Fund"},{"key":"2025100602581370900_ciaf116-B31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(16)30565-5","article-title":"Jared Baeten\u2014aiming to see off HIV","volume":"17","author":"Kirby","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025100602581370900_ciaf116-B32","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/S0140-6736(10)60705-2","article-title":"Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis","volume":"375","author":"Donnell","year":"2010","journal-title":"Lancet"},{"key":"2025100602581370900_ciaf116-B33","doi-asserted-by":"crossref","first-page":"e1002099","DOI":"10.1371\/journal.pmed.1002099","article-title":"Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda","volume":"13","author":"Baeten","year":"2016","journal-title":"PLoS Med"},{"key":"2025100602581370900_ciaf116-B34","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(21)00048-5","article-title":"Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study","volume":"8","author":"Donnell","year":"2021","journal-title":"Lancet HIV"},{"key":"2025100602581370900_ciaf116-B35","doi-asserted-by":"crossref","first-page":"e1730","DOI":"10.1016\/S2214-109X(21)00391-0","article-title":"Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial","volume":"9","author":"Irungu","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025100602581370900_ciaf116-B36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1071\/SH18090","article-title":"Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study","volume":"15","author":"Masyuko","year":"2018","journal-title":"Sex Health"},{"key":"2025100602581370900_ciaf116-B37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41591-020-0872-x","article-title":"PrEP rollout in Africa: status and opportunity","volume":"26","author":"Irungu","year":"2020","journal-title":"Nat Med"},{"key":"2025100602581370900_ciaf116-B38","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf116\/62892550\/ciaf116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/555\/62892550\/ciaf116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/3\/555\/62892550\/ciaf116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:58:22Z","timestamp":1759733902000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/3\/555\/8108801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf116","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,15]]},"published":{"date-parts":[[2025,4,9]]}}}